Very good news came for Synergy pharmaceuticals, the FDA approved expanded indication to treat irritable bowel for one of their products. However, according to some analysts seems that the company suffers from cash constipation (lol) which limits its access to loans with which it could exploit this product to the maximum.
I think it is quite interesting what can happen with this company in the next few days, I will be pending how it develops, obviously everything will depend on the level of certainty that may generate in investors, words like cash, loans and strategies will be key.